Elan, Biogen slide on Tysabri news :
"Shares of partners Elan and Biogen Idec slid on Monday after they announced that while the Food and Drug Administration has ruled to allow its recalled multiple sclerosis drug Tysabri back on the market, the drug's use will be significantly restricted."